ID   ROS1_HUMAN              Reviewed;        2347 AA.
AC   P08922; Q15368; Q5TDB5;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 3.
DT   12-OCT-2022, entry version 215.
DE   RecName: Full=Proto-oncogene tyrosine-protein kinase ROS;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:11094073};
DE   AltName: Full=Proto-oncogene c-Ros;
DE   AltName: Full=Proto-oncogene c-Ros-1;
DE   AltName: Full=Receptor tyrosine kinase c-ros oncogene 1;
DE   AltName: Full=c-Ros receptor tyrosine kinase;
DE   Flags: Precursor;
GN   Name=ROS1; Synonyms=MCF3, ROS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASN-2213; GLN-2228 AND CYS-2229.
RX   PubMed=2352949; DOI=10.1073/pnas.87.12.4799;
RA   Birchmeier C., O'Neill K., Riggs M., Wigler M.;
RT   "Characterization of ROS1 cDNA from a human glioblastoma cell line.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4799-4803(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1790-2260.
RX   PubMed=3023956; DOI=10.1128/mcb.6.8.3000-3004.1986;
RA   Matsushime H., Wang L.-H., Shibuya M.;
RT   "Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus
RT   encodes for a transmembrane receptorlike molecule.";
RL   Mol. Cell. Biol. 6:3000-3004(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1854-2347.
RX   PubMed=3785223; DOI=10.1128/mcb.6.9.3109-3116.1986;
RA   Birchmeier C., Birnbaum D., Waitches G., Fasano O., Wigler M.;
RT   "Characterization of an activated human ros gene.";
RL   Mol. Cell. Biol. 6:3109-3116(1986).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=8143271; DOI=10.1016/0165-4608(94)90128-7;
RA   Watkins D., Dion F., Poisson M., Delattre J.Y., Rouleau G.A.;
RT   "Analysis of oncogene expression in primary human gliomas: evidence for
RT   increased expression of the ros oncogene.";
RL   Cancer Genet. Cytogenet. 72:130-136(1994).
RN   [6]
RP   FUNCTION IN VAV3 ACTIVATION, INTERACTION WITH VAV3, AND CATALYTIC ACTIVITY.
RX   PubMed=11094073; DOI=10.1128/mcb.20.24.9212-9224.2000;
RA   Zeng L., Sachdev P., Yan L., Chan J.L., Trenkle T., McClelland M.,
RA   Welsh J., Wang L.H.;
RT   "Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase
RT   activity, modulates cell morphology, and induces cell transformation.";
RL   Mol. Cell. Biol. 20:9212-9224(2000).
RN   [7]
RP   DISEASE, CHROMOSOMAL TRANSLOCATION WITH GOPC, AND MUTAGENESIS OF LYS-1980.
RX   PubMed=12661006; DOI=10.1002/gcc.10207;
RA   Charest A., Lane K., McMahon K., Park J., Preisinger E., Conroy H.,
RA   Housman D.;
RT   "Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with
RT   an interstitial del(6)(q21q21).";
RL   Genes Chromosomes Cancer 37:58-71(2003).
RN   [8]
RP   PHOSPHORYLATION AT TYR-2274 AND TYR-2334, AND MUTAGENESIS OF TYR-2274 AND
RP   TYR-2334.
RX   PubMed=12538861; DOI=10.1073/pnas.242741799;
RA   Charest A., Kheifets V., Park J., Lane K., McMahon K., Nutt C.L.,
RA   Housman D.;
RT   "Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus
RT   in a glioblastoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:916-921(2003).
RN   [9]
RP   FUNCTION IN CELL PROLIFERATION AND DIFFERENTIATION, FUNCTION IN
RP   PHOSPHORYLATION OF PTPN11, AND INTERACTION WITH PTPN11.
RX   PubMed=16885344; DOI=10.1158/0008-5472.can-06-1193;
RA   Charest A., Wilker E.W., McLaughlin M.E., Lane K., Gowda R., Coven S.,
RA   McMahon K., Kovach S., Feng Y., Yaffe M.B., Jacks T., Housman D.;
RT   "ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-
RT   2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling
RT   axis to form glioblastoma in mice.";
RL   Cancer Res. 66:7473-7481(2006).
RN   [10]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-13; VAL-126; PRO-145; GLN-167; SER-224;
RP   CYS-338; PRO-370; HIS-419; MET-537; PHE-653; HIS-865; LEU-1109; PHE-1239;
RP   SER-1353; ARG-1370; GLY-1506; HIS-1776; LYS-1902; ASN-1999; ARG-2003;
RP   SER-2138; ASN-2203; GLU-2213; ASN-2213; GLN-2228; CYS-2229 AND LYS-2240.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Orphan receptor tyrosine kinase (RTK) that plays a role in
CC       epithelial cell differentiation and regionalization of the proximal
CC       epididymal epithelium. May activate several downstream signaling
CC       pathways related to cell differentiation, proliferation, growth and
CC       survival including the PI3 kinase-mTOR signaling pathway. Mediates the
CC       phosphorylation of PTPN11, an activator of this pathway. May also
CC       phosphorylate and activate the transcription factor STAT3 to control
CC       anchorage-independent cell growth. Mediates the phosphorylation and the
CC       activation of VAV3, a guanine nucleotide exchange factor regulating
CC       cell morphology. May activate other downstream signaling proteins
CC       including AKT1, MAPK1, MAPK3, IRS1 and PLCG2.
CC       {ECO:0000269|PubMed:11094073, ECO:0000269|PubMed:16885344}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:11094073};
CC   -!- ACTIVITY REGULATION: Inhibited by dephosphorylation by PTPN6.
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with PTPN6 (via SH2 1 domain); the interaction is
CC       direct and promotes ROS1 dephosphorylation (By similarity). Interacts
CC       with PTPN11; may activate the PI3 kinase-mTOR signaling pathway.
CC       Interacts with VAV3; constitutive interaction mediating VAV3
CC       phosphorylation. {ECO:0000250, ECO:0000269|PubMed:11094073,
CC       ECO:0000269|PubMed:16885344}.
CC   -!- INTERACTION:
CC       P08922; P18031: PTPN1; NbExp=3; IntAct=EBI-7371065, EBI-968788;
CC       P08922; P29350: PTPN6; NbExp=2; IntAct=EBI-7371065, EBI-78260;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass type I
CC       membrane protein {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Expressed in brain. Expression is increased in
CC       primary gliomas. {ECO:0000269|PubMed:8143271}.
CC   -!- PTM: Phosphorylated. Probably autophosphorylates. Phosphorylation at
CC       Tyr-2274 is required for the interaction with PTPN6 that mediates ROS1
CC       dephosphorylation (By similarity). Phosphorylation at Tyr-2274
CC       stimulates the kinase activity and the activation of the ERK1 signaling
CC       cascade (By similarity). Phosphorylation at Tyr-2274 and/or Tyr-2334
CC       recruits PTPN11. {ECO:0000250, ECO:0000269|PubMed:12538861}.
CC   -!- DISEASE: Note=A chromosomal aberration involving ROS1 is found in a
CC       glioblastoma multiforme sample. An intra-chromosomal deletion
CC       del(6)(q21q21) is responsible for the formation of GOPC-ROS1 chimeric
CC       protein which is localized to the Golgi and has a constitutive receptor
CC       tyrosine kinase activity. A SLC34A2-ROS1 chimeric protein produced in
CC       non-small cell lung cancer cells also retains a constitutive kinase
CC       activity. A third type of chimeric protein CD74-ROS1 was also
CC       identified in those cells. {ECO:0000269|PubMed:12661006}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M34353; AAA60278.1; -; mRNA.
DR   EMBL; Z98880; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL132671; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M13599; AAA60277.1; -; Genomic_DNA.
DR   EMBL; M13368; AAA60277.1; JOINED; Genomic_DNA.
DR   EMBL; M13591; AAA60277.1; JOINED; Genomic_DNA.
DR   EMBL; M13592; AAA60277.1; JOINED; Genomic_DNA.
DR   EMBL; M13593; AAA60277.1; JOINED; Genomic_DNA.
DR   EMBL; M13594; AAA60277.1; JOINED; Genomic_DNA.
DR   EMBL; M13595; AAA60277.1; JOINED; Genomic_DNA.
DR   EMBL; M13596; AAA60277.1; JOINED; Genomic_DNA.
DR   EMBL; M13597; AAA60277.1; JOINED; Genomic_DNA.
DR   EMBL; M13598; AAA60277.1; JOINED; Genomic_DNA.
DR   EMBL; M13880; AAA36580.1; -; mRNA.
DR   CCDS; CCDS5116.1; -.
DR   PIR; A35512; TVHURS.
DR   RefSeq; NP_002935.2; NM_002944.2.
DR   PDB; 3ZBF; X-ray; 2.20 A; A=1934-2232.
DR   PDB; 4UXL; X-ray; 2.40 A; A=1934-2232.
DR   PDBsum; 3ZBF; -.
DR   PDBsum; 4UXL; -.
DR   AlphaFoldDB; P08922; -.
DR   SMR; P08922; -.
DR   BioGRID; 112025; 7.
DR   IntAct; P08922; 99.
DR   MINT; P08922; -.
DR   STRING; 9606.ENSP00000357494; -.
DR   BindingDB; P08922; -.
DR   ChEMBL; CHEMBL5568; -.
DR   DrugBank; DB11986; Entrectinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P08922; -.
DR   GuidetoPHARMACOLOGY; 1840; -.
DR   GlyGen; P08922; 33 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; P08922; -.
DR   PhosphoSitePlus; P08922; -.
DR   BioMuta; ROS1; -.
DR   DMDM; 126302596; -.
DR   EPD; P08922; -.
DR   jPOST; P08922; -.
DR   MassIVE; P08922; -.
DR   PaxDb; P08922; -.
DR   PeptideAtlas; P08922; -.
DR   PRIDE; P08922; -.
DR   ProteomicsDB; 52177; -.
DR   ABCD; P08922; 2 sequenced antibodies.
DR   Antibodypedia; 32541; 684 antibodies from 35 providers.
DR   DNASU; 6098; -.
DR   Ensembl; ENST00000368508.7; ENSP00000357494.3; ENSG00000047936.11.
DR   GeneID; 6098; -.
DR   KEGG; hsa:6098; -.
DR   UCSC; uc003pxp.2; human.
DR   CTD; 6098; -.
DR   DisGeNET; 6098; -.
DR   GeneCards; ROS1; -.
DR   HGNC; HGNC:10261; ROS1.
DR   HPA; ENSG00000047936; Group enriched (epididymis, lung).
DR   MalaCards; ROS1; -.
DR   MIM; 165020; gene.
DR   neXtProt; NX_P08922; -.
DR   OpenTargets; ENSG00000047936; -.
DR   Orphanet; 357191; Selection of therapeutic option in non-small cell lung carcinoma.
DR   PharmGKB; PA34633; -.
DR   VEuPathDB; HostDB:ENSG00000047936; -.
DR   eggNOG; KOG1095; Eukaryota.
DR   GeneTree; ENSGT00940000160831; -.
DR   InParanoid; P08922; -.
DR   OrthoDB; 203310at2759; -.
DR   PhylomeDB; P08922; -.
DR   TreeFam; TF351636; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P08922; -.
DR   SignaLink; P08922; -.
DR   SIGNOR; P08922; -.
DR   BioGRID-ORCS; 6098; 8 hits in 1109 CRISPR screens.
DR   ChiTaRS; ROS1; human.
DR   GeneWiki; ROS1_(gene); -.
DR   GenomeRNAi; 6098; -.
DR   Pharos; P08922; Tclin.
DR   PRO; PR:P08922; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P08922; protein.
DR   Bgee; ENSG00000047936; Expressed in upper lobe of left lung and 58 other tissues.
DR   ExpressionAtlas; P08922; baseline and differential.
DR   Genevisible; P08922; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; ISS:UniProtKB.
DR   GO; GO:0002066; P:columnar/cuboidal epithelial cell development; ISS:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0032006; P:regulation of TOR signaling; IDA:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd00063; FN3; 7.
DR   Gene3D; 2.120.10.30; -; 3.
DR   Gene3D; 2.60.40.10; -; 7.
DR   InterPro; IPR011042; 6-blade_b-propeller_TolB-like.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000033; LDLR_classB_rpt.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00041; fn3; 3.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 9.
DR   SMART; SM00135; LY; 4.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 5.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50853; FN3; 9.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Chromosomal rearrangement;
KW   Glycoprotein; Kinase; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Proto-oncogene; Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL          1..27
FT                   /evidence="ECO:0000255"
FT   CHAIN           28..2347
FT                   /note="Proto-oncogene tyrosine-protein kinase ROS"
FT                   /id="PRO_0000016722"
FT   TOPO_DOM        28..1859
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1860..1882
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1883..2347
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          101..196
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          197..285
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          557..671
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          947..1042
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1043..1150
FT                   /note="Fibronectin type-III 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1450..1556
FT                   /note="Fibronectin type-III 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1557..1656
FT                   /note="Fibronectin type-III 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1658..1751
FT                   /note="Fibronectin type-III 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1752..1854
FT                   /note="Fibronectin type-III 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1945..2222
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          2284..2311
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        2079
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         1951..1959
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         1980
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   SITE            1852..1853
FT                   /note="Breakpoint for translocation to form SLC34A2-ROS1
FT                   and CD74-ROS1 fusion proteins"
FT   SITE            1880..1881
FT                   /note="Breakpoint for translocation to form GOPC-ROS1
FT                   fusion protein"
FT   MOD_RES         2274
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:12538861"
FT   MOD_RES         2334
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:12538861"
FT   CARBOHYD        52
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        114
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        123
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        324
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        352
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        396
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        471
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        607
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        628
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        706
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        714
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        732
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        939
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        961
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1015
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1087
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1090
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1095
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1211
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1272
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1330
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1458
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1461
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1474
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1499
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1565
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1669
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1715
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1738
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1808
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         13
FT                   /note="N -> S (in dbSNP:rs45606237)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041442"
FT   VARIANT         126
FT                   /note="G -> V (in dbSNP:rs34245787)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041443"
FT   VARIANT         145
FT                   /note="T -> P (in dbSNP:rs1998206)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_030648"
FT   VARIANT         167
FT                   /note="R -> Q (in dbSNP:rs2243380)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_030649"
FT   VARIANT         224
FT                   /note="P -> S (in dbSNP:rs55959124)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041444"
FT   VARIANT         338
FT                   /note="Y -> C (in dbSNP:rs55707658)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041445"
FT   VARIANT         370
FT                   /note="S -> P (in dbSNP:rs56274823)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041446"
FT   VARIANT         419
FT                   /note="Y -> H (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs1444274116)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041447"
FT   VARIANT         537
FT                   /note="I -> M (in dbSNP:rs28639589)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041448"
FT   VARIANT         653
FT                   /note="S -> F (in dbSNP:rs34203286)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041449"
FT   VARIANT         790
FT                   /note="N -> S (in dbSNP:rs34582164)"
FT                   /id="VAR_049712"
FT   VARIANT         865
FT                   /note="Q -> H (in a lung large cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041450"
FT   VARIANT         1109
FT                   /note="S -> L (in dbSNP:rs2229079)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_030650"
FT   VARIANT         1239
FT                   /note="Y -> F (in dbSNP:rs56192249)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041451"
FT   VARIANT         1353
FT                   /note="Y -> S (in dbSNP:rs35269727)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041452"
FT   VARIANT         1370
FT                   /note="C -> R (in dbSNP:rs36106063)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041453"
FT   VARIANT         1439
FT                   /note="F -> S (in dbSNP:rs17079086)"
FT                   /id="VAR_030651"
FT   VARIANT         1506
FT                   /note="R -> G (in dbSNP:rs35841892)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041454"
FT   VARIANT         1776
FT                   /note="D -> H (in dbSNP:rs12664076)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_030652"
FT   VARIANT         1902
FT                   /note="E -> K (in dbSNP:rs9489124)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_030653"
FT   VARIANT         1999
FT                   /note="H -> N (in dbSNP:rs45569132)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041455"
FT   VARIANT         2003
FT                   /note="K -> R (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041456"
FT   VARIANT         2039
FT                   /note="R -> H (in dbSNP:rs3752566)"
FT                   /id="VAR_030654"
FT   VARIANT         2138
FT                   /note="F -> S (in a gastric adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041457"
FT   VARIANT         2203
FT                   /note="D -> N (in dbSNP:rs556427413)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041458"
FT   VARIANT         2213
FT                   /note="D -> E (in dbSNP:rs75510639)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041459"
FT   VARIANT         2213
FT                   /note="D -> N (in dbSNP:rs529038)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:2352949"
FT                   /id="VAR_030655"
FT   VARIANT         2228
FT                   /note="K -> Q (in dbSNP:rs529156)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:2352949"
FT                   /id="VAR_041460"
FT   VARIANT         2229
FT                   /note="S -> C (in dbSNP:rs619203)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:2352949"
FT                   /id="VAR_030656"
FT   VARIANT         2240
FT                   /note="N -> K (in dbSNP:rs210968)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_030657"
FT   VARIANT         2328
FT                   /note="K -> R (in dbSNP:rs35932630)"
FT                   /id="VAR_049713"
FT   MUTAGEN         1980
FT                   /note="K->M: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:12661006"
FT   MUTAGEN         2274
FT                   /note="Y->F: Loss of phosphorylation at Y-2274 and loss of
FT                   interaction with PTPN11."
FT                   /evidence="ECO:0000269|PubMed:12538861"
FT   MUTAGEN         2334
FT                   /note="Y->F: Loss of phosphorylation at Y-2334 and loss of
FT                   interaction with PTPN11."
FT                   /evidence="ECO:0000269|PubMed:12538861"
FT   CONFLICT        2246..2260
FT                   /note="EDGDVICLNSDDIMP -> KFDSSEFSSFRCTVN (in Ref. 3;
FT                   AAA60277)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2262
FT                   /note="A -> V (in Ref. 1; AAA60278)"
FT                   /evidence="ECO:0000305"
FT   HELIX           1942..1944
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   STRAND          1945..1952
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   TURN            1955..1957
FT                   /evidence="ECO:0007829|PDB:4UXL"
FT   STRAND          1959..1965
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   TURN            1966..1968
FT                   /evidence="ECO:0007829|PDB:4UXL"
FT   STRAND          1974..1981
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   HELIX           1988..2002
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   STRAND          2012..2016
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   STRAND          2018..2021
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   STRAND          2023..2027
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   HELIX           2034..2043
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   HELIX           2053..2072
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   HELIX           2082..2084
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   STRAND          2085..2088
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   STRAND          2090..2094
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   STRAND          2098..2100
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   HELIX           2125..2127
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   HELIX           2130..2135
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   HELIX           2140..2155
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   HELIX           2167..2175
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   HELIX           2188..2197
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   HELIX           2202..2204
FT                   /evidence="ECO:0007829|PDB:3ZBF"
FT   HELIX           2208..2227
FT                   /evidence="ECO:0007829|PDB:3ZBF"
SQ   SEQUENCE   2347 AA;  263915 MW;  98902B9A59ACB8F5 CRC64;
     MKNIYCLIPK LVNFATLGCL WISVVQCTVL NSCLKSCVTN LGQQLDLGTP HNLSEPCIQG
     CHFWNSVDQK NCALKCRESC EVGCSSAEGA YEEEVLENAD LPTAPFASSI GSHNMTLRWK
     SANFSGVKYI IQWKYAQLLG SWTYTKTVSR PSYVVKPLHP FTEYIFRVVW IFTAQLQLYS
     PPSPSYRTHP HGVPETAPLI RNIESSSPDT VEVSWDPPQF PGGPILGYNL RLISKNQKLD
     AGTQRTSFQF YSTLPNTIYR FSIAAVNEVG EGPEAESSIT TSSSAVQQEE QWLFLSRKTS
     LRKRSLKHLV DEAHCLRLDA IYHNITGISV DVHQQIVYFS EGTLIWAKKA ANMSDVSDLR
     IFYRGSGLIS SISIDWLYQR MYFIMDELVC VCDLENCSNI EEITPPSISA PQKIVADSYN
     GYVFYLLRDG IYRADLPVPS GRCAEAVRIV ESCTLKDFAI KPQAKRIIYF NDTAQVFMST
     FLDGSASHLI LPRIPFADVK SFACENNDFL VTDGKVIFQQ DALSFNEFIV GCDLSHIEEF
     GFGNLVIFGS SSQLHPLPGR PQELSVLFGS HQALVQWKPP ALAIGANVIL ISDIIELFEL
     GPSAWQNWTY EVKVSTQDPP EVTHIFLNIS GTMLNVPELQ SAMKYKVSVR ASSPKRPGPW
     SEPSVGTTLV PASEPPFIMA VKEDGLWSKP LNSFGPGEFL SSDIGNVSDM DWYNNSLYYS
     DTKGDVFVWL LNGTDISENY HLPSIAGAGA LAFEWLGHFL YWAGKTYVIQ RQSVLTGHTD
     IVTHVKLLVN DMVVDSVGGY LYWTTLYSVE STRLNGESSL VLQTQPWFSG KKVIALTLDL
     SDGLLYWLVQ DSQCIHLYTA VLRGQSTGDT TITEFAAWST SEISQNALMY YSGRLFWING
     FRIITTQEIG QKTSVSVLEP ARFNQFTIIQ TSLKPLPGNF SFTPKVIPDS VQESSFRIEG
     NASSFQILWN GPPAVDWGVV FYSVEFSAHS KFLASEQHSL PVFTVEGLEP YALFNLSVTP
     YTYWGKGPKT SLSLRAPETV PSAPENPRIF ILPSGKCCNK NEVVVEFRWN KPKHENGVLT
     KFEIFYNISN QSITNKTCED WIAVNVTPSV MSFQLEGMSP RCFIAFQVRA FTSKGPGPYA
     DVVKSTTSEI NPFPHLITLL GNKIVFLDMD QNQVVWTFSA ERVISAVCYT ADNEMGYYAE
     GDSLFLLHLH NRSSSELFQD SLVFDITVIT IDWISRHLYF ALKESQNGMQ VFDVDLEHKV
     KYPREVKIHN RNSTIISFSV YPLLSRLYWT EVSNFGYQMF YYSIISHTLH RILQPTATNQ
     QNKRNQCSCN VTEFELSGAM AIDTSNLEKP LIYFAKAQEI WAMDLEGCQC WRVITVPAML
     AGKTLVSLTV DGDLIYWIIT AKDSTQIYQA KKGNGAIVSQ VKALRSRHIL AYSSVMQPFP
     DKAFLSLASD TVEPTILNAT NTSLTIRLPL AKTNLTWYGI TSPTPTYLVY YAEVNDRKNS
     SDLKYRILEF QDSIALIEDL QPFSTYMIQI AVKNYYSDPL EHLPPGKEIW GKTKNGVPEA
     VQLINTTVRS DTSLIISWRE SHKPNGPKES VRYQLAISHL ALIPETPLRQ SEFPNGRLTL
     LVTRLSGGNI YVLKVLACHS EEMWCTESHP VTVEMFNTPE KPYSLVPENT SLQFNWKAPL
     NVNLIRFWVE LQKWKYNEFY HVKTSCSQGP AYVCNITNLQ PYTSYNVRVV VVYKTGENST
     SLPESFKTKA GVPNKPGIPK LLEGSKNSIQ WEKAEDNGCR ITYYILEIRK STSNNLQNQN
     LRWKMTFNGS CSSVCTWKSK NLKGIFQFRV VAANNLGFGE YSGISENIIL VGDDFWIPET
     SFILTIIVGI FLVVTIPLTF VWHRRLKNQK SAKEGVTVLI NEDKELAELR GLAAGVGLAN
     ACYAIHTLPT QEEIENLPAF PREKLTLRLL LGSGAFGEVY EGTAVDILGV GSGEIKVAVK
     TLKKGSTDQE KIEFLKEAHL MSKFNHPNIL KQLGVCLLNE PQYIILELME GGDLLTYLRK
     ARMATFYGPL LTLVDLVDLC VDISKGCVYL ERMHFIHRDL AARNCLVSVK DYTSPRIVKI
     GDFGLARDIY KNDYYRKRGE GLLPVRWMAP ESLMDGIFTT QSDVWSFGIL IWEILTLGHQ
     PYPAHSNLDV LNYVQTGGRL EPPRNCPDDL WNLMTQCWAQ EPDQRPTFHR IQDQLQLFRN
     FFLNSIYKSR DEANNSGVIN ESFEGEDGDV ICLNSDDIMP VALMETKNRE GLNYMVLATE
     CGQGEEKSEG PLGSQESESC GLRKEEKEPH ADKDFCQEKQ VAYCPSGKPE GLNYACLTHS
     GYGDGSD
//
